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doi:10.1Objective: In addition to use of a laser, argon plasma coagulation, electrocautery, or coring with a rigid broncho-
scope, tumor debulking with a flexible cryoprobe is used for therapeutic bronchoscopy with an immediate effect
for endobronchial pathologies. We performed this analysis to determine the usefulness, efficacy, and safety of the
flexible cryorecanalization in a large population under routine conditions.
Methods: We identified 225 bronchoscopic interventions that were done as cryorecanalization with a flexible
cryoprobe. All patients had symptomatic airway stenosis. We determined the endoscopic success rate and safety
(bleeding and perforation) of the procedure.
Results: Successful cryorecanalization was achieved in 205 (91.1%) of 225 patients. The flexible cryoprobe
was used with all patients, in most patients in combination with flexible bronchoscopy and only in a minority
(n = 31, 13.8%) in combination with a rigid bronchoscope. Additional interventional techniques used were endo-
bronchial stents (n ¼ 11, 4.9%) and argon plasma coagulation (n ¼ 37, 16.4%). Mild bleeding (if ice-cold NaCl
or epinephrine solution was necessary) occurred in 9 (4.0%) patients, moderate bleeding (if argon plasma coag-
ulation or a bronchus blocker was required) occurred in 18 (8.0%) patients, and severe bleeding (events with he-
modynamic instability) never occurred.
Conclusions: Cryorecanalization with the flexible cryoprobe for treatment of symptomatic endobronchial tumor
stenosis is a safe technique with a high success rate and immediate treatment effect. (J Thorac Cardiovasc Surg
2010;139:997-1000)G
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SHemoptysis, cough, and dyspnea are the most frequent
symptoms of patients with exophytic tumor manifestations
in lung cancer.1-3 The high mortality of lung cancer is at least
partially caused by locally advanced tumor growth resulting
in atelectasis and pneumonia. Tumor obstruction of the cen-
tral or peripheral airways can result in postobstructive pneu-
monia, which is difficult to treat. In such a case, a safe and
effective bronchoscopic treatment modality is required to
resolve symptoms and complications caused by airway ob-
struction. In these cases many interventional pneumologists
use rigid bronchoscopy in combination with mechanical
debulking with forceps, a neodymium-doped yttrium alumi-
num garnet (Nd-YAG) laser, electrocautery, argon plasma
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The Journal of Thoracic and Caexophytic obstructing tumors.4-6 APC and brachytherapy
have the disadvantage that either a secondary bronchoscopy
is mandatory or they do not allow the immediate opening of
obstructed airways. For more detailed information regarding
the advantages and disadvantages of each method, we refer
the reader to the existing literature.7 The flexible cryoprobe,
introduced as a tool for immediate management of airway
stenosis, extends the options of interventional bronchos-
copy.8 The flexible probe can be used in combination with
the rigid bronchoscope to guarantee more safety during inter-
vention and allows the use of additional techniques, such as
stent implantation. Tracheal tubes allow the use of the cryo-
probe in a flexible technique as well. Its 7.5-mm working
channel enables therapeutic interventions with the cryo-
probe, which is 2.4 mm in diameter, or the combination
with APC in case of bleeding.9,10
The aim of this analysis was to evaluate the efficacy and
safety of the flexible cryoprobe for immediate tumor abla-
tion in patients with exophytic endobronchial or tracheal
tumor obstruction in a routine setting in a center with
much expertise with the use of the flexible cryoprobe.MATERIALS AND METHODS
Patients
We analyzed the data of all patients who underwent bronchoscopy in our
clinic from February 2001 to September 2007. In this series we identified all
patients undergoing bronchoscopic intervention with the flexible cryoprobe
because of an exophytic tumor of the trachea or bronchi with subsequentrdiovascular Surgery c Volume 139, Number 4 997
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garnetsymptomatic airway stenosis. In addition to the flexible cryoprobe, a laser or
APC, as well as mechanical debulking with a rigid scope, were available but
rarely used since the introduction of the flexible cryoprobe in our institution
in 2001. The local ethics committee approved this study.
For any bronchoscopic intervention, a platelet count of at least 100 Giga/
L and normal coagulation parameters (partial thromboplastin time<40 sec-
onds and prothrombin ratio>70%) were mandatory. Medications influenc-
ing clotting time were stopped before intervention; heparin was stopped at
least 12 hours before intervention.
Cryorecanalization
The flexible cryoprobe (Erbokryo; ERBE, Tu¨bingen, Germany) was
used as described previously.11 It can be used with the rigid bronchoscope
after achievement of general anesthesia but also with the flexible technique
in combination with a 7.5- or 8.5-mm Bronchoflex tube (Ru¨sch, Kernen,
Germany), which has separate oxygen tubing, after achievement of local
anesthesia and sedation. The decision of which method to apply, as well
as the use of additional techniques, was left to the discretion of the treating
physician and based on published guidelines.4,5 It should be noted that there
is no ideal interventional strategy that can fully guarantee success and a safe
outcome. The execution of any technique depends on the expertise of the
team and the personal skills of the physician. If possible, we preassigned
(in an expert discussion) the used interventional technique before each bron-
choscopy. In cases with stenosis caused by an endoluminal tumor, almost all
interventions were done as cryorecanalization (CR). In cases with mixed
stenosis (with an additionally extraluminal tumor), we combined the tech-
niques, such as CR and implantation of stents. Briefly, in general we used
the following interventional technique. First, the cryoprobe is introduced
through a flexible bronchoscope in combination with a flexible tube or
a rigid bronchoscope. Second, the tip of the cryoprobe is pushed into the
exophytic tumor mass, and freezing is started for 3 to 5 seconds with a foot-
pad. Freezing is achieved with the Joules–Thomson effect: nitrous oxide is
decompressed at the tip of the probe, which generates immediate cooling of
the tip to89 C. Third, the cryoprobe and the flexible bronchoscope are
abruptly mechanically removed, and thus a tumor mass of up to 10 mm is
frozen at the tip of the cryoprobe and can easily be extracted. Fourth, rapid
thawing of the extracted tissue is induced in a water bath for 5 seconds. Fi-
nally, the procedure is repeated until the exophytic tumor mass has been
extracted and the target bronchus is reopened. After CR, subsequent stent
implantation can be performed in the same session or APC can be used to
stop bleeding, if needed. Additionally, some factors could influence the in-
tervention. Among them, bleeding of the tumor limits visibility and can sig-
nificantly extend the procedural duration, which normally has a range of 15
to 60 minutes. Chest radiographic analysis was not performed routinely after
the intervention and remained at the discretion of the physician.
Procedural Success and Safety
We defined our criteria to determine the success rate of CR. The bron-
choscopist classified the intervention based on endoscopic criteria as (1) suc-
cessful if the endobronchial tumor mass could be ablated so that either
drainage of secretion or reduced airway stenosis led to a significant
improvement in the patient’s condition with amelioration of symptoms
(eg, dyspnea, fever, or cough) and (2) not successful or a failure if the primary
goal of the intervention (ie, target bronchus reopening) could not be reached.rnal of Thoracic and Cardiovascular SurgSafety data were evaluated regarding severity of bleeding, need for a res-
cue operation, or prolonged mechanical ventilation for longer than 2 hours
after the intervention. Bleeding was graded as mild if application of cold
NaCl 0.9% solution (2 C–4 C) or epinephrine solution (1 mg/10 mL
saline water) applied topically was sufficient to stop bleeding, moderate if
additional techniques (APC or a bronchus blocker) had to be used, and se-
vere if additional treatment was needed (transfusion of red blood cells, fresh
frozen plasma, or coagulation factors; use of vasopressors, rescue operation;
or prolonged mechanical ventilation) to stabilize the patient’s condition.
RESULTS
Patients
Between February 2001 and September 2007, 5308 con-
secutive bronchoscopies were performed in our clinic. In
this cohort bronchoscopic intervention with CR with the
flexible cryoprobe for treatment of symptomatic exophytic
tumor stenosis of the trachea or bronchi was used in 225
patients. The mean age of the patients was 63.9 12.9 years
(range, 19–83 years), and 193 (85.8%) were inpatients. One
hundred fifty-six (69.3%) patients were men.
Localization and Distribution of Obstructing Tumor
Lesions
CR of obstructing tumor lesions in the central airways
(trachea, main bronchus, and bronchus intermedius) was
performed in 99 (44.0%) patients, of the lobe bronchi in
93 (41.3%) patients, and simultaneously in the central air-
ways and lobe bronchi in 33 (14.7%) patients. Multifocal
endobronchial lesions (in>1 bronchus) were present in 67
(29.8%) patients and were treated with the flexible cryo-
probe within 1 interventional session. One hundred
twenty-four (55.1%) lesions were located in the right bron-
chial system, 64 (28.4%) lesions were located in the left
bronchial system, and 33 (14.7%) lesions were located in
the trachea or on the main carina. A detailed overview of
lesion localizations is shown in Table 1. In 197 (87.6%)
of 225 patients, airway stenosis was malignant. One hundred
forty-seven (74.6%) patients had lung cancer. Table 2
shows the histologic findings in detail.
Techniques
The majority of interventions (194 [86.2%] patients)
were performed solely with the flexible technique. The rigid
scope, always used in combination with the flexible bron-
choscope, was used in 31 (13.8%) patients. Additional tech-
niques were rarely needed: APC (in patients with prolonged
bleeding after CR) in 37 (16.4%) patients and stent implan-
tation in 11 (4.9%) patients.
Success Rate and Safety of CR
CR was successful in 205 (91.1%) of 225 interventions.
In 20 (8.9%) patients the intervention was not successful
and did not reopen the obstructed bronchus. The main reason
for unsuccessful interventions was a longer length (>2 cm)
of the complete bronchial obstruction.ery c April 2010
TABLE 1. Endobronchial localization and distribution of exophytic
tumor stenosis treated with cryorecanalization
Localization and distribution
of exophytic
tumor stenosis
No. of
lesions
Percentage of all lesions
treated with
cryorecanalization
Right bronchial system 131 58.2
Left bronchial system 68 30.2
Trachea 35 15.6
Bilateral localization 5 2.2
Central airways 132 58.7
Peripheral airways 124 55.1
Extended lesions 31 13.8
Multiple localization 49 21.8
Note: Summery of cases might exceed the total number of cases because of overlap-
ping lesional attribution. Bilateral localization, If cryorecanalization was performed
in both the right and left bronchial system of the patient in 1 session; Central airways,
trachea, left/right main bronchus, and bronchus intermedius; Peripheral airways, all
other bronchi, distal of defined central airways; Extended lesions, if cryorecanalization
was performed in both the central and peripheral airways in 1 session; multiple
localization, if tumor stenosis was found and treated in different lobular bronchi in
1 session.
TABLE 2. Overview on histologic findings
Conditions Patients, no. (%)
Nonmalignant lesions* 28 (12.4)
Malignant lesions 197 (87.6)
Lung cancer 147 (74.6)
SCLC 26 (17.7)
NSCLC 121 (82.3)
Adenocarcinoma 13 (10.7)
Squamous cell cancer 83 (68.6)
Other or not specified NSCLC 25 (20.7)
Other malignant lesionsy 50 (25.4)
SCLC, Small cell lung cancer; NSCLC, non–small cell lung cancer. *Nonmalignant
lesions were as follows: benign tracheal stenosis, lipoma, endobronchial granulation
tissue, and hamartoma. yOther malignant lesions were (number and percentage
of all malignant lesions) as follows: colorectal cancer (17 [8.63%]), carcinoid
(6 [3.05%]), lymphoma (6 [3.05%]), breast cancer (5 [2.54%]), ovarian carcinoma
(4 [2.03%]), esophageal carcinoma (4 [2.03%]), renal cell carcinoma (3 [1.52%]),
malignant melanoma (2 [1.02%]), thyroid cancer (2 [1.02%]), and laryngopharyngeal
carcinoma (1 [0.51%]).
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with mild bleeding in 9 (4.0%) patients and moderate bleed-
ing in 18 (8.0%) patients. Severe bleeding did not occur.
Thus the overall bleeding rate was low. No case of pneumo-
thorax was detected. One manifestation of pneumomediasti-
num was seen in a patient with a cystadenoma, a benign
tracheal tumor. In this patient injury of the pars membrana-
cea occurred after removal of the bulky tumor. The patient
was hospitalized and treated with antibiotics to prevent
mediastinitis. Surgical intervention was evaluated but not
necessary after spontaneous closure of the very small tra-
cheal perforation. The patient fully recovered after 5 days
without further complications.DISCUSSION
Patients with symptomatic bronchial obstruction caused
by an endoluminal exophytic tumor require immediate treat-
ment. Selection of the appropriate interventional technique
depends on the treatment plan (curative or palliative inten-
tion) and on the type of tumor stenosis (endoluminal, extra-
luminal, or mixed).5 The combination of both rigid and
flexible bronchoscopy is the most commonly and wide-
spread used method, and it allows additional use of APC,
an Nd-YAG laser, electrocautery, or CR. The main advan-
tage of the laser, electrocautery, and CR is their immediate
effect by tumor ablation. The flexible cryoprobe allows
recanalization within a single intervention without the
necessity of a secondary bronchoscopy. The cryoprobe can
be resterilized and reused without any restrictions in effec-
tiveness. CR or tumor debulking with a flexible cryoprobe
performed in the way that is described in this article is a rel-
atively new approach. The previously performed feasibility
study in our institution of 60 patients showed a high successThe Journal of Thoracic and Carate (83%) of CR with a moderate bleeding rate of 10%.8
The present study confirms the findings of the feasibility
study and showed that even under daily routine conditions
in the bronchoscopy suite, CR of exophytic endobronchial
tumor stenoses is safe and successful in about 91% of cases.
The success rate in our present study was even higher than in
the feasibility study.8 This might be explained by the learn-
ing curve of the CR procedure. A current chest computed
tomographic scan to estimate the distance and complexity
of the stenosis is mandatory before intervention to ensure
safety and for the appropriate selection of patients. We tried
to reopen longer tumor stenoses than were seen on the com-
puted tomographic scan. However, in these cases a lower
success rate has to be taken into account. This was also
the case in our study, in which the main reason for unsuc-
cessful intervention was a long tumor stenosis with infiltra-
tive tumor growth. The duration of pre-existing tumor
stenosis (as measured from the onset of symptoms) did not
seem to influence the procedural success rate, even if partial
atelectasis or mediastinal shift was seen. It was frequently
possible to reopen 4- to 6-week-old tumor obstructions suc-
cessfully by using CR.11
We found a higher rate of moderate compared with mild
bleeding in our study. Because the freezing has a hemostatic
effect on minor bleeding lesions, it is likely that this is not suf-
ficient in cases with severe tumor-associated bleeding. On the
other hand, mild bleeding often occurs during bronchoscopic
interventions in patients with lung cancer and is not always
routinely reported as an adverse event. Therefore it can be as-
sumed that the rate of mild bleeding is underestimated with
conventional bronchoscopic techniques. However, with
strict attention to normal coagulation parameters and platelet
counts before the intervention, there was no severe bleeding
complication in our study. For safety reasons, CR was not
done if chest computed tomographic scans showed tumor
involvement of large vessels in the interventional region.rdiovascular Surgery c Volume 139, Number 4 999
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the flexible cryoprobe is that it can easily be performed with
both flexible and rigid techniques. Compared with the
Nd-YAG laser, which is still the standard technique in large
institutions, cost for purchase, repair, and maintenance for
the less invasive techniques of APC, electrocautery, and
CR are lower.5 A cost-effectiveness study revealed that the
average treatment cost for the Nd-YAG laser was 20%
higher compared with that for electrocautery, which was
caused by a longer hospital stay before bronchoscopic treat-
ment.12 Another advantage of CR is that large particles of
tumor can be extracted with the flexible cryoprobe. Thus
the time for effective tumor mass ablation is generally
shorter compared with that for laser therapy. The shorter
intervention time is one of the reasons why so many CRs
in our clinic could be performed with the flexible bronchos-
copy technique. Furthermore, the study shows clearly that
the use of a tracheal tube as a working channel (instead of
the rigid scope) is a feasible and safe option and allows
a completely flexible interventional technique.
APC, which is also used for treatment of malignant airway
stenosis, requires a second bronchoscopic intervention for
the removal of devitalized tissue 48 to 72 hours after initial
APC treatment.10 We achieved a higher procedural success
rate compared with that seen after APC. Reichle and col-
leagues13 showed the efficacy of APC in 186 patients with
malignant airway stenosis. They achieved ‘‘good results’’
in only 67% of cases. Moreover, one has to take into account
that in this study more than 90% of interventions were per-
formed with rigid bronchoscopy. In contrast, the rigid bron-
choscope was used in only 13.8% of interventions in our
study. However, APC and CR can be effectively combined
and do not exclude each other. We successfully used APC to
stop bleeding after application of the cryoprobe in 16.4% of
patients.
In conclusion, CR is a safe and successful method for
endobronchial exophytic tumor debulking. The flexible
cryoprobe is easy to use and allows rapid removal of exo-
phytic tumors under direct observation with low bleeding
rates. CR can be regarded as an alternative primary tool
and complementary method to APC, electrocautery, or the
Nd-YAG laser for endobronchial tumors. This study showed
promising safety data for the routine use of the flexible cryo-1000 The Journal of Thoracic and Cardiovascular Surprobe over the long-term. The main advantage of CR is its
immediate effect on tumor stenosis with subsequent rapid
improvement of the patient’s symptoms. For future studies,
we recommend additionally evaluating patient-related
outcomes with the dyspnea scale and quality-of-life
instruments.
The purpose of this nonrandomized study was to describe
the safety and efficacy of a flexible cryoprobe as a primary
tool for endobronchial recanalization in malignant lesions.
As a retrospective study, a per-protocol patient selection
was not conducted. However, a prospective randomized
study will follow to compare different interventional
methods regarding safety, efficacy, and selection strategies
for each technique.
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